Atrial Fibrillation (A-FIB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Atrial Fibrillation

MalaCards integrated aliases for Atrial Fibrillation:

Name: Atrial Fibrillation 12 37 29 55 6 43 3 44 15 63 63 17 72
Fibrillation, Atrial 40
a-Fib 12


External Ids:

Disease Ontology 12 DOID:0060224
KEGG 37 H00731
ICD9CM 35 427.31
MeSH 44 D001281
NCIt 50 C50466
SNOMED-CT 68 49436004
UMLS 72 C0004238

Summaries for Atrial Fibrillation

PubMed Health : 63 About atrial fibrillation: Atrial fibrillation (A-tre-al fi-bri-LA-shun), or AF, is the most common type of arrhythmia (ah-RITH-me-ah). An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. AF occurs if rapid, disorganized electrical signals cause the heart's two upper chambers—called the atria (AY-tree-uh)—to fibrillate. The term "fibrillate" means to contract very fast and irregularly. In AF, blood pools in the atria. It isn't pumped completely into the heart's two lower chambers, called the ventricles (VEN-trih-kuls). As a result, the heart's upper and lower chambers don't work together as they should. People who have AF may not feel symptoms. However, even when AF isn't noticed, it can increase the risk of stroke. In some people, AF can cause chest pain or heart failure, especially if the heart rhythm is very rapid. AF may happen rarely or every now and then, or it may become an ongoing or long-term heart problem that lasts for years.

MalaCards based summary : Atrial Fibrillation, also known as fibrillation, atrial, is related to familial atrial fibrillation and short qt syndrome, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Atrial Fibrillation is KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q Member 1), and among its related pathways/superpathways are Vascular smooth muscle contraction and Adrenergic signaling in cardiomyocytes. The drugs Prednisolone phosphate and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney, and related phenotypes are no effect and cardiovascular system

Disease Ontology : 12 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain.

MedlinePlus : 43 An arrhythmia is a problem with the speed or rhythm of the heartbeat. Atrial fibrillation (AF) is the most common type of arrhythmia. The cause is a disorder in the heart's electrical system. Often, people who have AF may not even feel symptoms. But you may feel Palpitations -- an abnormal rapid heartbeat Shortness of breath Weakness or difficulty exercising Chest pain Dizziness or fainting Fatigue Confusion AF can lead to an increased risk of stroke. In many patients, it can also cause chest pain, heart attack, or heart failure. Doctors diagnose AF using family and medical history, a physical exam, and a test called an electrocardiogram (EKG), which looks at the electrical waves your heart makes. Treatments include medicines and procedures to restore normal rhythm. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Atrial fibrillation, often called AFib or AF, is the most common type of heart arrhythmia. An arrhythmia is when the heart beats too slowly, too fast, or in an irregular way. When a person has AFib, the normal beating in the upper chambers of the heart (the two atria) is irregular, and blood doesn't flow as well as it should from the atria to the lower chambers of the heart (the two ventricles). AFib may occur in brief episodes, or it may be a permanent condition.

KEGG : 37
Atrial fibrillation (AF, ATFB) is the most common cardiac arrhythmia and is regarded generally as a sporadic, acquired disorder. Nevertheless, recent growing evidence points to an important heritable basis for AF. By linkage analysis, several loci have been mapped for monogenetic AF. Some of these loci encode for subunits of potassium channels.

Wikipedia : 75 Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular... more...

Related Diseases for Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 830)
# Related Disease Score Top Affiliating Genes
1 familial atrial fibrillation 33.6 SCN5A SCN4B SCN3B SCN2B SCN1B PITX2
2 short qt syndrome 33.3 KCNQ1 KCNJ2 KCNH2 KCNE2
3 cardiac arrhythmia 32.8 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2
4 congestive heart failure 32.7 NPPB NPPA ACE
5 heart valve disease 32.6 NPPB NPPA ACE
6 mitral valve insufficiency 32.5 NPPB NPPA ACE
7 progressive familial heart block, type ia 32.3 SCN5A GJA5
8 ventricular fibrillation, paroxysmal familial, 1 32.3 SCN5A KCNQ1 KCNH2 KCNE2
9 atrial standstill 1 32.3 SCN5A SCN1B NPPB GJA5 ACE
10 atrioventricular block 32.3 SCN5A NPPB KCNQ1 KCNH2 KCNE2
11 cardiac conduction defect 32.2 SCN5A KCNQ1 KCNH2
12 coronary artery anomaly 32.1 NPPB NPPA ACE
13 syncope 32.1 SCN5A NPPB NPPA KCNQ1 KCNJ2 KCNH2
14 left bundle branch hemiblock 31.9 SCN5A NPPB ACE
15 acute myocardial infarction 31.9 NPPB NPPA ACE
16 right bundle branch block 31.8 SCN5A SCN3B SCN2B SCN1B
17 pulmonary edema 31.8 NPPB NPPA ACE
18 cardiac arrest 31.7 SCN5A NPPB KCNQ1 KCNH2 ACE
19 pulmonary hypertension 31.7 NPPB NPPA KCNA5 ACE
20 heart disease 31.7 SCN5A PITX2 NPPB NPPA KCNQ1 KCNJ2
21 atrial standstill 31.6 SCN5A NPPA GJA5
22 central sleep apnea 31.5 NPPB NPPA
23 third-degree atrioventricular block 31.5 SCN5A NPPB KCNE2
24 dilated cardiomyopathy 31.5 SCN5A NPPB NPPA KCNQ1 KCNH2 GJA5
25 first-degree atrioventricular block 31.5 SCN5A GJA5
26 diastolic heart failure 31.4 NPPB NPPA ACE
27 aortic valve disease 2 31.4 NPPB NPPA MYL4 ACE
28 long qt syndrome 31.2 SCN5A SCN4B SCN1B KCNQ1 KCNJ2 KCNH2
29 familial short qt syndrome 31.1 KCNQ1 KCNJ2 KCNH2
30 catecholaminergic polymorphic ventricular tachycardia 31.1 SCN5A KCNJ2 KCNH2
31 brugada syndrome 31.0 SCN5A SCN4B SCN3B SCN2B SCN1B KCNQ1
32 tetralogy of fallot 31.0 PITX2 NPPB NPPA KCNH2 GJA5
33 familial progressive cardiac conduction defect 30.9 SCN5A SCN1B
34 long qt syndrome 3 30.9 SCN5A KCNQ1 KCNH2 KCNE2
35 brugada syndrome 1 30.7 SCN5A KCNH2 KCNA5
36 anterolateral myocardial infarction 30.7 NPPB NPPA ACE
37 long qt syndrome 1 30.7 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2 KCNE2
38 long qt syndrome 5 30.6 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2
39 andersen cardiodysrhythmic periodic paralysis 30.6 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2
40 long qt syndrome 2 30.5 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2
41 jervell and lange-nielsen syndrome 1 30.5 SCN5A SCN4B KCNQ1 KCNH2 KCNE2
42 sudden infant death syndrome 30.3 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNH2
43 timothy syndrome 29.9 KCNQ1 KCNH2
44 atrial fibrillation, familial, 15 12.9
45 atrial fibrillation, familial, 3 12.9
46 atrial fibrillation, familial, 11 12.9
47 atrial fibrillation, familial, 6 12.9
48 atrial fibrillation, familial, 7 12.9
49 atrial fibrillation, familial, 10 12.9
50 atrial fibrillation, familial, 4 12.9

Graphical network of the top 20 diseases related to Atrial Fibrillation:

Diseases related to Atrial Fibrillation

Symptoms & Phenotypes for Atrial Fibrillation

UMLS symptoms related to Atrial Fibrillation:

angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Atrial Fibrillation according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ABCC9 ACE GJA5 KCNA5 KCNE2 KCNH2

MGI Mouse Phenotypes related to Atrial Fibrillation:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ABCC9 ACE GJA5 KCNA5 KCNH2 KCNJ2
2 behavior/neurological MP:0005386 10.02 ACE KCNJ2 KCNQ1 MYL4 PITX2 SCN1B
3 homeostasis/metabolism MP:0005376 10 ABCC9 ACE GJA5 KCNA5 KCNE2 KCNH2
4 muscle MP:0005369 9.61 ABCC9 GJA5 KCNA5 KCNH2 KCNJ2 KCNQ1
5 nervous system MP:0003631 9.32 KCNA5 KCNQ1 NUP155 PITX2 SCN1B SCN2B

Drugs & Therapeutics for Atrial Fibrillation

PubMed Health treatment related to Atrial Fibrillation: 63

Treatment for atrial fibrillation (AF) depends on how often you have symptoms, how severe they are, and whether you already have heart disease. General treatment options include medicines, medical procedures, and lifestyle changes.

Drugs for Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 517)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
carbamide peroxide Approved Phase 4 124-43-6
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
Atorvastatin Approved Phase 4 134523-00-5 60823
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Dalteparin Approved Phase 4 9005-49-6
Sodium citrate Approved, Investigational Phase 4 68-04-2
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Verapamil Approved Phase 4 52-53-9 2520
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Histamine Approved, Investigational Phase 4 51-45-6 774
Antazoline Approved Phase 4 91-75-8 2200
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Procainamide Approved Phase 4 51-06-9 4913
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
Terazosin Approved Phase 4 63590-64-7 5401
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
Ramipril Approved Phase 4 87333-19-5 5362129
Ezetimibe Approved Phase 4 163222-33-1 150311
Nifedipine Approved Phase 4 21829-25-4 4485
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
Pantoprazole Approved Phase 4 102625-70-7 4679
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Dipyridamole Approved Phase 4 58-32-2 3108
Metolazone Approved Phase 4 17560-51-9 4170
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
Tolvaptan Approved Phase 4 150683-30-0 216237
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
Nitric Oxide Approved Phase 4 10102-43-9 145068
44 Bemiparin Approved, Investigational Phase 4 91449-79-5
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
Cefpirome Approved Phase 4 84957-29-9 5479539
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Ethinyl Estradiol Approved Phase 4 57-63-6 5991

Interventional clinical trials:

(show top 50) (show all 2656)
# Name Status NCT ID Phase Drugs
1 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
2 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
3 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
4 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
5 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
6 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
7 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
8 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
9 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2 Unknown status NCT01504451 Phase 4
10 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
11 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
12 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
13 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
14 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
15 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
16 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
17 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
18 Relationship Between Catheter Contact Force and Electrogram Characteristics in Fibrillating Human Atrial Myocardium Unknown status NCT01587404 Phase 4
19 Comparison of Acute Pulmonary Vein (PV) Reconnection Between Contact Force Guided and Blinded PV Isolation in Patients With Symptomatic Atrial Fibrillation Unknown status NCT02924181 Phase 4
20 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
21 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
22 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
23 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
24 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
25 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
26 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
27 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
28 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
29 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
30 Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control Unknown status NCT02025465 Phase 4 Metoprolol;Diltiazem
31 Phase Ⅳ Study of CARTO 3D Mapping System vs Conventional Method in AF & VT Unknown status NCT00959205 Phase 4
32 Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF) Unknown status NCT02637453 Phase 4
33 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
34 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
35 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
36 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
37 "Bidirectional Conduction Block of Left Atrial Anterior Line in Patients With Left Atrial Ablation - Reduction of RF Applications Using the Thermocool SmartTouch Contact Force Sensing Catheter Unknown status NCT02217657 Phase 4
38 Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin
39 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
40 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
41 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
42 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
43 AMIOCAAF (AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation): a Randomized Controlled Trial - Vanguard Phase Unknown status NCT02341105 Phase 4 Amiodarone
44 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
45 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
46 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
47 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
48 Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
49 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
50 Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo

Search NIH Clinical Center for Atrial Fibrillation

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Digitalis preparation
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide Phosphate
ibutilide fumarate
metoprolol succinate
Metoprolol Tartrate
Procainamide Hydrochloride
Propafenone Hydrochloride
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol Hydrochloride
Verapamil hydrochloride
Warfarin Sodium

Cochrane evidence based reviews: atrial fibrillation

Genetic Tests for Atrial Fibrillation

Genetic tests related to Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Atrial Fibrillation 29

Anatomical Context for Atrial Fibrillation

MalaCards organs/tissues related to Atrial Fibrillation:

Heart, Testes, Kidney, Brain, Lung, Endothelial, Thyroid

Publications for Atrial Fibrillation

Articles related to Atrial Fibrillation:

(show top 50) (show all 30404)
# Title Authors PMID Year
Pharmacologic and Nonpharmacologic Management of Atrial Fibrillation. 38 17
31378329 2019
Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation. 38 17
31378330 2019
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 71
21810866 2011
Arrhythmias in Congenital Heart Disease. 17
31378336 2019
Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation. 9 38
20483000 2010
Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. 9 38
20466203 2010
Association of ADRB1 gene polymorphism with atrial fibrillation. 9 38
20384459 2010
Predictive value of B-type natriuretic peptide for postoperative atrial fibrillation following pulmonary resection for lung cancer. 9 38
19896864 2010
Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. 9 38
20117462 2010
Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack. 9 38
19845751 2010
Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. 9 38
20170814 2010
Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. 9 38
20083826 2010
Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation. 9 38
20063294 2010
Serum N-terminal-pro-brain natriuretic peptide level and its clinical implications in patients with atrial fibrillation. 9 38
20014208 2009
[Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients]. 9 38
20066882 2009
Genetic polymorphism of KCNH2 confers predisposition of acquired atrial fibrillation in Chinese. 9 38
19490382 2009
[Associations of the genetic polymorphisms in CYP11B2 gene with nonfamilial structural atrial fibrillation]. 9 38
20193392 2009
Utility of brain natriuretic peptide as a predictor of atrial fibrillation after cardiac operations. 9 38
19699901 2009
Predicting successful pulmonary vein isolation in patients with atrial fibrillation by brain natriuretic Peptide plasma levels. 9 38
19763191 2009
Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. 9 38
19778674 2009
Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation. 9 38
19632626 2009
The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. 9 38
18619686 2009
Heart failure may be associated with the onset of ischemic stroke with atrial fibrillation: a brain natriuretic peptide study. 9 38
19321180 2009
Comprehensive mutation scanning of LMNA in 268 patients with lone atrial fibrillation. 9 38
19427440 2009
Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. 9 38
19265792 2009
Effect of Angiotensin converting enzyme inhibitors and Angiotensin receptor blockers on patients following ablation of atrial fibrillation. 9 38
19949577 2009
Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation. 9 38
18996572 2009
Study of the factors related to atrial fibrillation after coronary artery bypass grafting: a search for a marker to predict the occurrence of atrial fibrillation before surgical intervention. 9 38
19327514 2009
Effects of exercise testing on natriuretic peptide secretion in patients with atrial fibrillation. 9 38
19378231 2009
Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolic stroke? 9 38
19327599 2009
Gain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing. 9 38
19167345 2009
Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease. 9 38
19117407 2009
Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. 9 38
18201783 2009
Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. 9 38
19118720 2009
Brain natriuretic peptide correlates with the extent of atrial fibrillation-associated silent brain lesions. 9 38
18823968 2008
A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. 9 38
18929244 2008
The predictive value of plasma brain natriuretic peptide for the recurrence of atrial fibrillation six months after external cardioversion. 9 38
19155659 2008
Letter by Hong et al regarding article, "Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation". 9 38
18852373 2008
Progeria caused by a rare LMNA mutation p.S143F associated with mild myopathy and atrial fibrillation. 9 38
18339564 2008
Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. 9 38
18794401 2008
Mechanisms by which atrial fibrillation-associated mutations in the S1 domain of KCNQ1 slow deactivation of IKs channels. 9 38
18599533 2008
Plasma B-type natriuretic peptide predicts atrial fibrillation during rehabilitation after cardiac surgery. 9 38
18677172 2008
Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. 9 38
18638595 2008
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. 9 38
18614783 2008
Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. 9 38
18598963 2008
[The incidence and predictors of atrial fibrillation in hypertrophic cardiomyopathy]. 9 38
19040064 2008
[Clinical characteristics of patients with persistent atrial fibrillation referred for cardioversion: Spanish Cardioversion Registry (REVERSE)]. 9 38
18570785 2008
Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. 9 38
18496132 2008
X-linked nonsyndromic sinus node dysfunction and atrial fibrillation caused by emerin mutation. 9 38
18266676 2008
[Comparison of peripheral blood hematopoietic progenitor cells among patients with paroxysmal, permanent atrial fibrillation or sinus rhythm]. 9 38
19100027 2008

Variations for Atrial Fibrillation

ClinVar genetic disease variations for Atrial Fibrillation:

6 (show all 21)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 KCNQ1 NM_000218.2(KCNQ1): c.418A> G (p.Ser140Gly) single nucleotide variant Pathogenic rs120074192 11:2549189-2549189 11:2527959-2527959
2 SCN5A NM_000335.4(SCN5A): c.1410C> G (p.Asn470Lys) single nucleotide variant Pathogenic rs199473115 3:38646328-38646328 3:38604837-38604837
3 KCNQ1 NM_000218.2(KCNQ1): c.625T> C (p.Ser209Pro) single nucleotide variant Pathogenic rs199472705 11:2592575-2592575 11:2571345-2571345
4 KCNQ1 NM_000218.2(KCNQ1): c.421G> A (p.Val141Met) single nucleotide variant Pathogenic/Likely pathogenic rs199472687 11:2549192-2549192 11:2527962-2527962
5 SCN5A NM_000335.4(SCN5A): c.1963G> A (p.Glu655Lys) single nucleotide variant Likely pathogenic rs199473579 3:38640469-38640469 3:38598978-38598978
6 SCN5A NM_000335.4(SCN5A): c.5621T> C (p.Met1874Thr) single nucleotide variant Likely pathogenic rs199473324 3:38592239-38592239 3:38550748-38550748
7 SCN5A NM_000335.4(SCN5A): c.5848G> A (p.Val1950Met) single nucleotide variant Conflicting interpretations of pathogenicity rs41315493 3:38592012-38592012 3:38550521-38550521
8 KCNJ2 NM_000891.2(KCNJ2): c.277G> A (p.Val93Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs147750704 17:68171457-68171457 17:70175316-70175316
9 KCNE2 NM_172201.1(KCNE2): c.79C> T (p.Arg27Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs74315449 21:35742856-35742856 21:34370557-34370557
10 SCN5A NM_000335.4(SCN5A): c.4475A> G (p.Lys1492Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs199473260 3:38597211-38597211 3:38555720-38555720
11 SCN5A NM_000335.4(SCN5A): c.5473C> T (p.Arg1825Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs199473635 3:38592387-38592387 3:38550896-38550896
12 SCN5A NM_000335.4(SCN5A): c.3389C> T (p.Thr1130Ile) single nucleotide variant Uncertain significance rs199473197 3:38618271-38618271 3:38576780-38576780
13 SCN5A NM_000335.4(SCN5A): c.414G> A (p.Met138Ile) single nucleotide variant Uncertain significance rs199473060 3:38663959-38663959 3:38622468-38622468
14 SCN5A NM_000335.4(SCN5A): c.5958C> A (p.Asn1986Lys) single nucleotide variant Uncertain significance rs199473335 3:38591902-38591902 3:38550411-38550411
15 SCN5A NM_000335.4(SCN5A): c.1333C> G (p.His445Asp) single nucleotide variant Uncertain significance rs199473112 3:38647447-38647447 3:38605956-38605956
16 SCN5A NM_000335.4(SCN5A): c.1282G> A (p.Glu428Lys) single nucleotide variant Uncertain significance rs199473111 3:38647498-38647498 3:38606007-38606007
17 MYH7 NM_000257.4(MYH7): c.5190G> T (p.Met1730Ile) single nucleotide variant Uncertain significance 14:23884683-23884683 14:23415474-23415474
18 SCN5A NM_000335.4(SCN5A): c.5848G> T (p.Val1950Leu) single nucleotide variant Benign/Likely benign rs41315493 3:38592012-38592012 3:38550521-38550521
19 KCNH2 NM_000238.3(KCNH2): c.2690A> C (p.Lys897Thr) single nucleotide variant Benign/Likely benign rs1805123 7:150645534-150645534 7:150948446-150948446
20 KCNE2 NM_172201.1(KCNE2): c.269A> G (p.Glu90Gly) single nucleotide variant not provided rs199473366 21:35743046-35743046 21:34370747-34370747
21 KCNQ1 NM_000218.2(KCNQ1): c.440A> G (p.Gln147Arg) single nucleotide variant not provided rs199472689 11:2549211-2549211 11:2527981-2527981

Expression for Atrial Fibrillation

Search GEO for disease gene expression data for Atrial Fibrillation.

Pathways for Atrial Fibrillation

Pathways related to Atrial Fibrillation according to KEGG:

# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270
2 Adrenergic signaling in cardiomyocytes hsa04261

Pathways related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
10 11.15 SCN5A SCN4B SCN3B SCN2B